How GH Actually Turns Into IGF-1 — And the 3 Things That Matter More Than Your Dose

Here's a question I get constantly, in some form or another: "My IGF-1 lab came back at 265 after a few months on a growth-hormone peptide. I raised the dose. My next lab came back at 250 — lower than before, on a higher dose. What happened?"

That question trips people up because it seems to break the logic of dosing. More drug, less effect? But it only looks broken if you assume the peptide is the whole story. It isn't. The peptide's job is to raise growth hormone. What you actually feel — the recovery, the body composition, the joint feel, the collagen — comes from IGF-1, which your liver makes downstream of GH, and that conversion step is gated by three things that have nothing to do with your syringe.

Get those three things right and a modest GH signal converts efficiently. Get them wrong and doubling the dose can leave you exactly where you started — or somewhere worse. Here's the mechanism, in plain terms, and the three levers that actually move the needle.

The mechanism: GH is the signal, the liver does the work

Picture it as a three-step relay:

1. Something raises GH. A GH-secretagogue peptide — CJC-1295 on the GHRH receptor, Ipamorelin on the ghrelin receptor, the CJC-1295 / Ipamorelin blend hitting both — nudges your own pituitary to release a physiologic pulse of growth hormone. Exogenous HGH (covered in the GH/IGF-1 exogenous reference) skips that step and floods GH directly.
2. GH circulates. On fat and connective tissue, it does direct work — including breaking down fat via hormone-sensitive lipase. That's the mechanism behind "GH before bed, fasted" fat-loss timing.
3. In the liver, GH tries to trigger IGF-1 production — but it needs help. The liver requires available substrate (amino acids, energy) and an insulin signal to actually flip on IGF-1 output. Eating carbs after a fasted GH pulse is what supplies that insulin trigger. This insulin-dependency of hepatic IGF-1 production is well-established endocrinology, going back to foundational work on the GH/IGF-1 axis in the 1980s.
4. IGF-1 does the job you actually wanted. Muscle protein synthesis, collagen synthesis, tissue repair, satellite cell activation. IGF-1 is the molecule doing the work; GH is just the memo that tells the liver to make it.

The frame worth keeping: GH is the coach calling the play. IGF-1 is the player who has to actually execute it. More coaching doesn't score points if the player can't get on the field — and whether they can is decided by the three signals below.

The three signals that gate the conversion

If your IGF-1 labs aren't tracking with your GH dose, one of these three is under-dialed. It's rarely the peptide.

1. Caloric and protein intake. The liver can't build IGF-1 out of nothing — it needs raw material and the insulin signal that eating provides. Run a GH-secretagogue while aggressively cutting calories for fat loss, and the conversion stalls regardless of dose. If IGF-1-mediated benefits (recovery, muscle preservation, joint feel) are the goal, calorie and protein intake need to be high enough to fund the conversion. Get lean first if that's the priority, then eat to support the conversion once body composition is where you want it.

2. Estrogen (E2) in a healthy range. Estrogen participates in hepatic IGF-1 production, and estrogen crashed too low blunts the output. This shows up most clearly in men running aromatase inhibitors aggressively — E2 drops out of range, and a protocol that worked fine last cycle produces nothing this cycle. For men running exogenous hormones, a common target is keeping E2 in the 40-60 pg/mL range while on a GH-axis protocol. Most people not manipulating their hormones don't need to think about this — normal endogenous E2 handles it. It becomes relevant specifically when someone layers an aromatase inhibitor on top of a GH-axis peptide without realizing the two work against each other.

3. Training intensity that creates real demand. Your body doesn't build a hormone axis it doesn't need. A training session that produces genuine adaptation demand upregulates the recovery axis, IGF-1 included. The same weights every week with no progressive overload doesn't send that signal, and IGF-1 output stays flat no matter the GH dose. Foundation first: if nutrition, training intensity, and sleep aren't dialed, adding more peptide won't fix the output. The peptide is the amplifier, not the foundation.

That reader question from the top — 186 baseline, up to 265 on a lower dose, down to 250 on a higher one — is what happens when the dose moves but one of these three signals doesn't scale with it. More GH had no unclaimed conversion capacity to use. Raising the dose again usually just adds side effects without adding IGF-1.

Timing changes which effect you get

Once the three signals are dialed, when you take a GH-axis peptide determines which downstream effect dominates — because the same molecule does two different jobs depending on the metabolic context it lands in.

For most people chasing recovery, body composition, and joint feel together, pre-bed fasted is the default — it captures both effects in sequence. Post-workout dosing shifts the balance toward the anabolic side at some cost to the fat-loss window.

It doesn't matter where the GH came from

This is the part that matters commercially and honestly: the same three-signal gate applies whether the GH came from your own pituitary pulse (via Sermorelin, Tesamorelin, or a secretagogue blend) or from an injection of recombinant HGH. The liver runs the identical conversion either way. That means the case for the secretagogue path isn't "these are stronger than HGH" — they aren't. It's that a physiologic pulse, with the pituitary's own feedback brake intact, produces the same IGF-1 endpoint as exogenous HGH once the three signals are handled, with a lighter side-effect surface and no prescription required. Exogenous HGH remains the right tool for a diagnosed adult GH deficiency or an advanced protocol run through a supervising clinician — most people chasing recovery and body composition don't need to start there.

Side effects when the GH signal rises — and how to titrate them

Any time GH is genuinely elevated, from any source, a small cluster of side effects gets more likely. They're a function of the GH signal, not the specific peptide, and they're managed the same way regardless of which one drove the pulse.

Water retention. GH temporarily changes how your kidneys handle sodium and water, and that takes 3-4 weeks to normalize. You may notice puffiness in the hands and face or joint pressure during that window — it's the kidney recalibrating, not the peptide malfunctioning. If it's uncomfortable, drop the dose for 2-3 weeks and titrate back up slowly. Morning dosing tends to produce less noticeable retention than pre-bed dosing, because the natural cortisol peak at wake-up has a mild diuretic effect that offsets it.

Thyroid interaction. GH speeds up how fast your body converts T4 (inactive thyroid hormone) into T3 (the active form). For most people that's a feature — it amplifies the fat-loss signal. But if you're on levothyroxine for Hashimoto's or hypothyroidism, the accelerated conversion can burn through your prescribed dose faster than it was calculated for. If you're on thyroid medication and starting a GH-axis protocol, plan on checking labs and being ready to adjust the levothyroxine dose upward with your prescriber.

The honest caveat. Elevated IGF-1 is the class-level concern that applies to anything that raises GH-axis output long-term — active malignancy or a personal history of cancer is a reason to skip elective GH-axis use. At the pulse-pattern doses secretagogues produce, glucose and insulin-resistance concerns aren't a routine issue; they matter more at chronic, high-dose exogenous HGH use.

The takeaway

If your IGF-1 labs aren't moving the way your GH dose says they should, don't reach for more dose first. Check whether you're eating enough to fund the conversion, whether your estrogen is in range, and whether your training is actually producing an adaptation demand. Fix those three, give the timing a few weeks to work, and titrate side effects with dose rather than muscling through them. The peptide is doing its job — the conversion is where the real leverage is.

-- Rick

Sources: The insulin-dependent regulation of hepatic IGF-1 production is foundational endocrinology tracing to GH/IGF-1 axis research from the 1980s onward (the Yakar/LeRoith/Ho line of work on liver-specific GH receptor and IGF-1 knockout models). Tesamorelin's FDA approval (as Egrifta) for HIV-associated lipodystrophy is the strongest clinical dossier in the GH-secretagogue class. See also the GH/IGF-1 exogenous compound reference for how Somatropin, IGF-1 DES, and PEG-MGF compare to the secretagogue path, and the CJC-1295 / Ipamorelin deep-dive for dosing and cycling detail.

Educational information only, not medical advice. Peptides discussed here are sold for research use only and are not FDA-approved for human use except where noted.